Replies to post #133461 on Biotech Values

[DewDiligence]

I’m surprised MYL even bothered.

Could be more of a public relations move (helping sick people in poor countries) than an economic one.

[DewDiligence]

JNJ is taking heat for its unwillingness to allow cheap generics for its HIV drugs in poor countries:

http://www.ft.com/intl/cms/s/0/d6ca3afa-2cbf-11e1-b485-00144feabdc0.html#axzz1hNrqY9l8

Right or wrong, what JNJ doesn’t need these days is more bad publicity, so I’m surprised by the company’s deportment on this matter.